Skip to main content

Advertisement

SpringerLink
Log in

Anaplastic Glioma: Treatment Approaches in the Era of Molecular Diagnostics

  • Neuro-oncology (GJ Lesser, Section Editor)
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

The treatment paradigm for anaplastic glioma has shifted, owing to new diagnostic criteria and new phase III clinical trial evidence. In 2016, the WHO classification of brain tumors including diffuse gliomas was redefined to include molecular criteria, often supplanting the morphological appearance of the tumor cells. This was necessary as prognosis is more closely associated with molecular diagnosis than with morphology and grade. Recently, the benefit of adjuvant chemotherapy in addition to radiotherapy has been demonstrated in both anaplastic oligodendroglioma and anaplastic astrocytoma, as well as lower grade gliomas with the most marked benefit evident in IDH-mutated (astrocytoma) and 1p/19q co-deleted (oligodendroglial) tumors. The defining principle of recent breakthroughs has been the benefit of combinatorial therapy (chemo-radiation) as opposed to treatment in series or treatment of either modality after a period of observation upon evidence of progression.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Cahill DP, Louis DN, Cairncross JG. Molecular background of oligodendroglioma: 1p/19q, IDH, TERT, CIC and FUBP1. CNS Oncol. 2015;4(5):287–94.

    Article  CAS  Google Scholar 

  2. •• Loruis D, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee W, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803–20 This article summarizes the WHO 2016 revision of brain tumor diagnoses.

  3. • Eckel-Passow JE, Lachance DH, Molinaro AM, Walsh KM, Decker PA, Sicotte H, et al. Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med. 2015;372(26):2499–508 Characterizes glioma based on molecular profile, with the demonstration that the genetics of glioma (even low grade) are highly predictive of behavior, and in many cases more important than histological grade.

    Article  CAS  Google Scholar 

  4. Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D, Buckner J, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol. 2013;31(3):337–43.

    Article  CAS  Google Scholar 

  5. van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol. 2013;31(3):344–50.

    Article  Google Scholar 

  6. •• van den Bent MJ, Baumert B, Erridge SC, Vogelbaum MA, Nowak AK, Sanson M, et al. Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. Lancet. 2017;390(10103):1645–53 Demonstrated the benefit of adjuvant TMZ in anaplastic astrocytoma.

    Article  Google Scholar 

  7. Cairncross G, Berkey B, Shaw E, et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol. 2006;24:2707–14.

    Article  CAS  Google Scholar 

  8. Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer. 2000;83(5):588–93.

    Article  CAS  Google Scholar 

  9. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–96.

    Article  CAS  Google Scholar 

  10. Medical Research Council Brain Tumor Working Party. Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial. J Clin Oncol. 2001;19(2):509–18.

    Article  Google Scholar 

  11. Cairncross JG, Wang M, Jenkins RB, Shaw EG, Giannini C, Brachman DG, et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. J Clin Oncol. 2014;32(8):783–90.

    Article  CAS  Google Scholar 

  12. Co-del-“Radiation Therapy With Concomitant And Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy In Patients With Anaplastic Glioma Or Low Grade Glioma - Full Text View - Clinicaltrials.Gov.” Clinicaltrials.gov. N. p., 2017. Web. 24 Oct. 2017.

  13. • Osswald M, Jung E, Sahm F, Solecki G, Venkataramani V, Blaes J, et al. Brain tumor cells interconnect to a functional and resistant network. Nature. 2015;528(7580):93–8 Demonstrates the implications at a cellular level of the 1p/19q codeletion.

    CAS  PubMed  Google Scholar 

  14. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10):997–1003.

    Article  CAS  Google Scholar 

  15. • Buckner JC, Shaw EG, Pugh SL, Chakravarti A, Gilbert MR, Barger GR, et al. Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma. N Engl J Med. 2016;374(14):1344–55 Further demonstrates the benefit of adjuvant PCV chemotherapy in low-grade glioma (IDH-mutated with or without 1p/19q codeletion).

    Article  CAS  Google Scholar 

  16. Mellinghoff, IK et al. Phase 1 study of AG-881, an inhibitor of mutant IDH1/IDH2, in patients with advanced IDH-mutant solid tumors, including glioma. J Clin Oncol 36, 2018 (suppl; abstr 2002).

  17. Platten M. A mutation-specific peptide vaccine targeting IDH1R132H in patients with newly diagnosed malignant astrocytomas: a first-in-man multicenter phase I clinical trial of the German Neurooncology Working Group (NOA-16). J Clin Oncol 36, 2018 (suppl; abstr 2001).

Download references

Author information

Authors and Affiliations

  1. Division of Neuro-Oncology Mayo Clinic, Rochester, MN, USA

    Michael W. Ruff MD & Joon Uhm MD

  2. Division of Medical Oncology Mayo Clinic, Rochester, MN, USA

    Michael W. Ruff MD & Joon Uhm MD

Authors
  1. Michael W. Ruff MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joon Uhm MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael W. Ruff MD.

Ethics declarations

Conflict of Interest

Michael W. Ruff and Joon Uhm declare they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Neuro-oncology

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ruff, M.W., Uhm, J. Anaplastic Glioma: Treatment Approaches in the Era of Molecular Diagnostics. Curr. Treat. Options in Oncol. 19, 61 (2018). https://doi.org/10.1007/s11864-018-0579-0

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11864-018-0579-0

Keywords

Search

Navigation